In view of the exact downstream molecules of SCF/c-KIT signaling involved in the process, CRC cells were further treated with specific inhibitors of AKT, JNK, and extracellular signal-regulated kinases (ERK) pathways, respectively. This evidence concerns the gene AKT1 and colorectal carcinoma.